Gaucherís disease is a rare genetic disorder in which certain harmful fatty substances accumulate to excessive levels in different body organs. It arises due to the lack of an enzyme called glucocerebrosidase. Hence the disease is also called glucocerebrosidase deficiency. It belongs to a group of diseases called glycolipid storage diseases.
Children with the infantile form of the disease usually die within a year, but those who develop the disease later in life may survive for many years. The disease is most common among Ashkenazi (Eastern European) Jews.
Gaucherís disease is of three types:
Type 1 is a chronic form and is the most common one.
Type 2 is the infantile form usually causes death in the first year of life.
Type 3 is a juvenile form that can begin at any time during childhood.
Deposition of the fatty substances can occur in liver, spleen, lungs, bone marrow and, less commonly, brain. This can affect the normal functioning of the body, cause organ enlargement and bone pain. The disease can occur at any age. Treatment involves enzyme replacement.
Causes and Risk Factors of Gaucherís disease
Gaucherís disease arises due the lack of an enzyme called glucocerebrosidase. This enzyme normally breaks down fatty substances (lipids) called glucocerebrosides. The deficiency of the enzyme hence leads to the accumulation of lipids in different organs and tissues. The disease arises due to genetic mutations. More than 300 genetic mutations have been found to be associated with Gaucherís disease.
The disease is an inherited one that follows a pattern called autosomal recessive, i.e. both parents must be carriers of the genetic mutation that causes Gaucherís disease for their child to develop the condition.
The risk of developing Gaucherís disease or being a carrier increases if there is a family history of any type of Gaucherís disease. People of Eastern or Central European Jewish (Ashkenazi) ancestry are at high risk of having type 1 Gaucherís disease or being a carrier. Types 2 and 3 can occur in any ethnic group.
Latest Publications and Research on Gaucherís DiseaseAccuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data. - Published by PubMed
Dual-action ambroxol in treatment of chronic pain in Gaucher Disease. - Published by PubMed
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1. - Published by PubMed
Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. - Published by PubMed
Semaphorin 7A: a novel marker of disease activity in Gaucher disease. - Published by PubMed